Kejie advised 3SBio Inc. on its acquisition of worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of USD6.25 million.  Pegsiticase is being developed for the treatment of refractory gout and tumor lysis syndrome.

3SBio Inc. is a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products.  On February 7, 3SBio’s ADSs were successfully listed on the NASDAQ Global Market of the NASDAQ Stock Market LLC under the symbol “SSRX”.

Kejie’s team includes firm’s partner Fred Hao, associate Li Xin and legal assistant He Fen.